Announced FDA acceptance of BLA filing of PRX-102 for the treatment of Fabry disease
Top-line data from the BRIGHT study expected by end of first quarter, 2021
Management to host conference call and live webcast today, October 29, at 8:30 am ET
PR Newswire
CARMIEL, Israel, Oct. 29, 2020